scholarly journals Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse

Blood ◽  
1994 ◽  
Vol 83 (11) ◽  
pp. 3377-3383 ◽  
Author(s):  
F van Rhee ◽  
F Lin ◽  
JO Cullis ◽  
A Spencer ◽  
NC Cross ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Chronic Myeloid Leukemia ◽  
Bone Marrow Transplant ◽  
Myeloid Leukemia ◽  
Marrow Transplant ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Allogeneic Bone Marrow Transplant ◽  
Unrelated Donors ◽  
Polymerase Chain

Fourteen patients with chronic myeloid leukemia (CML) relapsing after allogeneic bone marrow transplant (BMT) were treated with leukocyte transfusions from the original marrow donor (sibling, n = 9; volunteer unrelated, n = 5). The relapse was defined at the molecular level in two cases, cytogenetically in five cases and hematologically in seven cases. Ten patients responded, seven of seven patients with cytogenetic/molecular relapse compared with three of seven with hematologic relapse (P < .03). All five recipients of cells from unrelated donors responded. Eight of the 10 responders have achieved polymerase chain reaction-negative status and this persisted in three patients for more than 2 years; no responder has shown sign of relapse. Reversible marrow aplasia occurred in two patients, both treated in hematologic relapse. Severe graft-versus-host disease occurred in four patients and was fatal in one. We confirm previous reports that donor leukocyte transfusions are effective in the management of CML in relapse after BMT. In this series, therapeutic intervention before the onset of hematologic relapse was associated with an increased likelihood of response and no marrow aplasia.

scholarly journals Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse

Blood ◽  
1994 ◽  
Vol 83 (11) ◽  
pp. 3377-3383 ◽  
Author(s):  
F van Rhee ◽  
F Lin ◽  
JO Cullis ◽  
A Spencer ◽  
NC Cross ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Chronic Myeloid Leukemia ◽  
Bone Marrow Transplant ◽  
Myeloid Leukemia ◽  
Marrow Transplant ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Allogeneic Bone Marrow Transplant ◽  
Unrelated Donors ◽  
Polymerase Chain

Abstract Fourteen patients with chronic myeloid leukemia (CML) relapsing after allogeneic bone marrow transplant (BMT) were treated with leukocyte transfusions from the original marrow donor (sibling, n = 9; volunteer unrelated, n = 5). The relapse was defined at the molecular level in two cases, cytogenetically in five cases and hematologically in seven cases. Ten patients responded, seven of seven patients with cytogenetic/molecular relapse compared with three of seven with hematologic relapse (P < .03). All five recipients of cells from unrelated donors responded. Eight of the 10 responders have achieved polymerase chain reaction-negative status and this persisted in three patients for more than 2 years; no responder has shown sign of relapse. Reversible marrow aplasia occurred in two patients, both treated in hematologic relapse. Severe graft-versus-host disease occurred in four patients and was fatal in one. We confirm previous reports that donor leukocyte transfusions are effective in the management of CML in relapse after BMT. In this series, therapeutic intervention before the onset of hematologic relapse was associated with an increased likelihood of response and no marrow aplasia.

OUTCOME OF ALLOGENEIC BONE MARROW TRANSPLANT FOR IRAQI PATIENTS WITH ACUTE MYELOID LEUKEMIA

2021 ◽  
Vol 74 (9) ◽  
pp. 2247-2254
Author(s):  
Alaadin Sahham Naji ◽  
Athmar Kadhim Gata ◽  
Luma Essa Hamodi ◽  
Mazin Abass ◽  
Fawaz Salim Yousif
Keyword(s):  
Bone Marrow ◽  
Overall Survival ◽  
Acute Myeloid Leukemia ◽  
Bone Marrow Transplant ◽  
Myeloid Leukemia ◽  
Marrow Transplant ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Allogeneic Bone Marrow Transplant ◽  
Acute Myeloid

The aim: To assess the outcome of allogeneic transplant regarding the overall Survival (OS) and main predictors can effect the survival of such patients. Materials and methods: The records of seventy-nine Iraqi patients diagnosed with non-promyelocytic AML, who underwent allogeneic bone marrow transplantation outside of Iraq between 2012 and 2019, had been reviewed. The information had been collected from the data available in Bone Marrow Transplant Centre in Baghdad Medical City. Overall survival had been calculated by Kaplan-Meier Method. Patients included in the study are those who were diagnosed with acute myeloid leukemia according to French American British classes with the exclusion of acute promyelocytic leukemia (M3), who were allotransplanted for being diagnosed with high risk cytogenetic, refractory to chemotherapeutic regimen, relapsed after achieving complete remission, secondary to transformation from other myeloid malignancies or remaining with positive measurable residual disease after treatment. Results: The overall survival for 1 year, 2 years and 3 years were 63.20%, 55.09% and 46.58% respectively. The pre-transplanted factors found, no significant difference in overall survival regarding age, gender, extra medullary involvement. The transplant related criteria like stem cell source, presence of infection and type of conditioning regimen and incidence of any post-transplant complications do not predict overall survival apart from chronic graft versus host disease. Chronic GVHD were found to be significantly affecting overall survival. Conclusions: The most common cause of death was disease relapse. Iraqi AML patients who were treated with allogeneic bone marrow transplant had shown to have encouraging overall survival.

Successful pregnancy after allogeneic bone marrow transplant with embryos isolated before transplant.

1997 ◽  
Vol 15 (11) ◽  
pp. 3347-3349 ◽  
Author(s):  
J H Lipton ◽  
M Virro ◽  
H Solow
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplant ◽  
Myeloid Leukemia ◽  
Marrow Transplant ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Cytotoxic Therapy ◽  
Successful Pregnancy ◽  
Allogeneic Bone Marrow Transplant

METHODS AND RESULTS: Autologous embryos from in vitro-fertilized ova were successfully implanted in a 29-year-old woman, 2 years after successful allogeneic bone marrow transplant (BMT) for chronic myeloid leukemia (CML). A second pregnancy, similarly initiated, is in progress at 4 years posttransplant. CONCLUSION: Our experience offers a fertility-salvaging technique to some women after cytotoxic therapy, where time permits ovarian hyperstimulation before the need for definitive myeloblative therapy of their malignancy, and where the risk of subsequent infertility is high.

Sign in / Sign up

Export Citation Format

Share Document